Takeda announces that the FDA has granted a priority assessment to the additional request for a new drug for ALUNBRIG?(brigatinib)
?....
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]- ALUNBRIG has the potential to broaden its indication for ALK + metastatic non-small cell lung cancer -
- Under the Prescription Drug User Fee Act (PDUFA), the target date is June 23, 2020 -
CAMBRIDGE, Massachusetts, and OSAKA, Japan - (?BUSINESS WIRE?) -? Takeda Announces FDA Has Prioritized the Additional Request for New Drug for ALUNBRIG???(brigatinib)?as First-?Line?Treatment for Cancer Cancer ALK + metastatic non-small cell lung?
T?akeda Pharmaceutical Company Limited?(TSE: 4502 / NYSE: TAK)?announces today that the United States Food and Drug Administration has granted a priority review to the company's Supplemental New Drug Request (sNDA) in preparation for to expand the use of ALUNBRIG (brigatinib) as a first-line treatment for patients with metastatic non-small cell lung cancer like ALK + (anaplastic lymphoma kinase) detected by an FDA approved test .?ALUNBRIG is a new generation tyrosine kinase (ITK) inhibitor designed to target and inhibit genetic alterations in ALK.
??NSCLC ALK + is a rare and serious form of lung cancer that is difficult to treat.?Although progress has been made, unmet needs still exist for approximately 40,000 patients who are diagnosed worldwide each year, "said Christopher Arendt, head of the Oncology Therapy Unit at Takeda.?"?This is an important first step in expanding treatment options for people with metastatic ALK + NSCLC in the United States, and we look forward to continuing to work alongside regulatory authorities around the world to offer ALUNBRIG to newly diagnosed patients.?" The sNDA for ALUNBRIG as a first-line treatment is based on the results of the ALTA-1L Phase 3 trial, which evaluates the safety and efficacy profile of ALUNBRIG in patients with NSCLC. Locally advanced or metastatic ALK + that has not already received treatment with an ALK inhibitor, compared to that of crizotinib in the same population.?The ALTA-1L trial met its primary endpoint, ALUNBRIG demonstrating superiority over crizotinib in terms of progression-free survival (PFS) assessed blindly by an independent review committee. About the ALTA-1L trial The ALTA-1L (?A?LK in?L?ung Cancer?T?rial of Brig?A?tinib in?1?st?L?ine) Phase 3 trial of ALUNBRIG in adults is a current, randomized, open, comparative and multicenter global study of 275 patients (ALUNBRIG, n = 137, crizotinib, n = 138) suffering from locally advanced or metastatic NSCLC already never treated with an ALK inhibitor.?Patients received either 180 mg ALUNBRIG once daily with a seven-day preparatory phase to 90 mg once daily, or 250 mg crizotinib twice daily. The median age was 58 years in the ALUNBRIG group and 60 years in the crizotinib group.?Twenty-nine percent of patients had baseline brain metastases in the ALUNBRIG group, and 30% in the crizotinib group.?Twenty-six percent of patients had previously received chemotherapy for an advanced or metastatic disease in the ALUNBRIG group, compared to 27% in the crizotinib group. Progression-free survival (PFS), assessed blindly by an independent review committee (IEC), was the primary endpoint.?Secondary endpoints included objective response rate (ORR) according to RECIST v1.1, intracranial ORT, intracranial PFS, overall survival (OS), safety and tolerability. The safety profile of ALUNBRIG during the ALTA-1L trial was generally consistent with current prescribing information in the United States. About ALUNBRIG???(brigatinib) ALUNBRIG is a new generation, powerful and selective tyrosine kinase (ITK) inhibitor, designed to target and inhibit genetic alterations in the anaplastic lymphoma kinase (ALK).?In April 2017, ALUNBRIG received accelerated approval from the Food and Drug Administration (?FDA?) for the treatment of patients with metastatic ALK + NSCLC who have had their disease progressed by taking crizotinib or who are intolerant to it.?This indication is approved under expedited authorization based on the tumor response rate and the duration of the response.?Continued authorization for this indication may be subject to verification and description of the clinical benefits as part of a confirmatory trial. ALUNBRIG is currently approved in more than 40 countries, including the United States, Canada and the European Union, for the treatment of patients with ALK + metastatic NSCLC who have worsened during treatment with crizotinib or who cannot tolerate taking crizotinib. ALUNBRIG received revolutionary FDA treatment designation for the treatment of ALK + NSCLC patients whose tumors are resistant to crizotinib, and received the FDA orphan drug designation for the treatment of ALK +, ROS1 + NSCLC EGFR +. About NSC + ALK + Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for about 85% of the 1.8 million new cases of lung cancer diagnosed worldwide each year, according to the World Organization of health.?1,2?Genetic studies indicate that chromosomal rearrangements of anaplastic lymphoma kinase (?ALK?) are key drivers in a subgroup of patients with NSCLC.?3?Between three and five percent of patients with metastatic NSCLC have a rearrangement of the?ALK?gene?.?4,5,6 Takeda is committed to continuing its research and development efforts for the NSCLC to improve the lives of the approximately 40,000 patients diagnosed with this serious and rare form of lung cancer each year worldwide.?7 Takeda's commitment to lung cancer Takeda is committed to diversifying the therapeutic options against NSCLC ALK + and NSCLC with mutation of EGFR / HER2.?Our comprehensive programs include the following clinical trials to continue to meet the unmet needs of people with lung cancer: ALUNBRIG- Phase 1/2?trial to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ALUNBRIG.?This essay has completed its recruitment.
- Pivotal Phase 2 ALTA?trial evaluating the efficacy and safety of ALUNBRIG with two dosages in patients with locally advanced or metastatic ALK + NSCLC who progressed during treatment with crizotinib.?This essay has completed its recruitment.
- Global randomized?ALTA-1L Phase 3?trial evaluating the efficacy and safety of ALUNBRIG compared to crizotinib in patients with locally advanced or metastatic ALK + NSCLC who have not yet received treatment with an ALK inhibitor.?This essay has completed its recruitment.
- Single-group, multicenter?J-ALTA Phase 2?trial in Japanese patients with ALK + NSCLC targeting patients with disease progression while taking alectinib.?This essay has completed its recruitment.
- Phase 2?, global, single-group?ALTA 2?trial evaluating ALUNBRIG in patients with advanced ALK + NSCLC who progressed while taking alectinib or ceritinib.?This essay has completed its recruitment.
- A?global, randomized?Phase 3 ALTA 3?trial comparing the efficacy and safety of ALUNBRIG versus alectinib in participants with NSCLC ALK + who progressed while taking crizotinib.?This trial is currently in the recruitment phase.
- Phase 1/2 study?evaluating the safety, pharmacokinetics and antitumor activity of TAK-788, an EGFR / HER2 inhibitor, orally in patients with NSCLC.?This essay has completed its recruitment.
- EXCLAIM Phase 2 pivotal extension cohort from?the Phase 1/2 trial to assess the efficacy and safety of TAK-788 at a single daily dose of 160 mg in previously treated patients with d mutations insertion into exon 20 of the EGFR.?This essay has completed its recruitment.
- EXCLAIM 2 Phase 3?Global Randomized?Study Evaluating?the Efficacy of TAK-788 as a First-Line Treatment Compared to Double Platinum-Based Chemotherapy in Treatment-Na?ve Patients with Locally Advanced NSCLC or metastatic whose tumors include insertion mutations in exon 20 of EGFR.?This trial is currently in the recruitment phase.
- Phase 1?, open, multicenter, increasing dose study evaluating the safety, tolerability and pharmacokinetics of TAK-788 in Japanese patients with locally advanced or metastatic NSCLC.?This essay has completed its recruitment.
- Open and multicenter?J-EXCLAIM Phase 2?study evaluating the efficacy of TAK-788 as a first-line treatment in Japanese patients with locally advanced or metastatic NSCLC whose tumors have insertion mutations in exon 20 of the EGFR.?This trial is currently in the recruitment phase.
- Phase 1?, open, two-?phase?, fixed-sequence study to characterize the drug-drug interaction between TAK-788 and a potent cytochrome P-450 (CYP) 3A inhibitor, itraconazole (part 1), or a strong inducer of CYP3A, rifampin (part 2), in healthy adult subjects.?This trial is currently in the recruitment phase.
Share this article on WhatsApp, LinkedIn and Twitter
Incisive News in 3 Shots.
Contact Us
- First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
- +91-120 428 0707
- connect@pharmashots.com
- Newsletter
Our Information
Modal title
Modal body text goes here.